Literature DB >> 26037320

Syntheses and evaluation of substituted aromatic hydroxamates and hydroxamic acids that target Mycobacterium tuberculosis.

Mark W Majewski1, Sanghyun Cho2, Patricia A Miller1, Scott G Franzblau2, Marvin J Miller3.   

Abstract

Tuberculosis (TB) continues to remain one of the most threatening diseases in the world. With the emergence of multi-drug resistant (MDR) and extensively drug resistant (XDR) strains, the need to develop new therapies is dire. The syntheses of a focused library of hydroxamates and hydroxamic acids is described, as well as anti-TB activity in the microplate alamar blue assay (MABA). A number of compounds exhibited good activity against Mtb, with notable compounds exhibiting MIC values in the range of 20-0.71 μM. This work suggests that both hydroxamates and their free acids may be incorporated into more complex scaffolds and serve as potential leads for the development of anti-TB agents.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hydroxamate; Hydroxamic acid; Tuberculosis

Mesh：

Substances：

Year:  2015        PMID： 26037320      PMCID： PMC4607592          DOI： 10.1016/j.bmcl.2015.04.099

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  21 in total

1.  Additional drug resistance in Mycobacterium tuberculosis isolates from resected cavities among patients with multidrug-resistant or extensively drug-resistant pulmonary tuberculosis.

Authors:  Russell R Kempker; Alexander S Rabin; Ketino Nikolaishvili; Iagor Kalandadze; Shota Gogishvili; Henry M Blumberg; Sergo Vashakidze
Journal:  Clin Infect Dis       Date:  2011-12-23       Impact factor: 9.079

2.  Virtual screening against metalloenzymes for inhibitors and substrates.

Authors:  John J Irwin; Frank M Raushel; Brian K Shoichet
Journal:  Biochemistry       Date:  2005-09-20       Impact factor: 3.162

3.  A library of novel hydroxamic acids targeting the metallo-protease family: design, parallel synthesis and screening.

Authors:  Marion Flipo; Terence Beghyn; Julie Charton; Virginie A Leroux; Benoit P Deprez; Rebecca F Deprez-Poulain
Journal:  Bioorg Med Chem       Date:  2006-10-12       Impact factor: 3.641

Review 4.  Advances in the development of new tuberculosis drugs and treatment regimens.

Authors:  Alimuddin Zumla; Payam Nahid; Stewart T Cole
Journal:  Nat Rev Drug Discov       Date:  2013-05       Impact factor: 84.694

5.  Benzothiazinones are suicide inhibitors of mycobacterial decaprenylphosphoryl-β-D-ribofuranose 2'-oxidase DprE1.

Authors:  Claudia Trefzer; Henrieta Škovierová; Silvia Buroni; Adela Bobovská; Simone Nenci; Elisabetta Molteni; Florence Pojer; Maria R Pasca; Vadim Makarov; Stewart T Cole; Giovanna Riccardi; Katarína Mikušová; Kai Johnsson
Journal:  J Am Chem Soc       Date:  2011-12-21       Impact factor: 15.419

6.  Design and Syntheses of Anti-Tuberculosis Agents Inspired by BTZ043 Using a Scaffold Simplification Strategy.

Authors:  Rohit Tiwari; Ute Möllmann; Sanghyun Cho; Scott G Franzblau; Patricia A Miller; Marvin J Miller
Journal:  ACS Med Chem Lett       Date:  2014-03-03       Impact factor: 4.345

7.  Syntheses of mycobactin analogs as potent and selective inhibitors of Mycobacterium tuberculosis.

Authors:  Raúl E Juárez-Hernández; Scott G Franzblau; Marvin J Miller
Journal:  Org Biomol Chem       Date:  2012-08-16       Impact factor: 3.876

Review 8.  Rising to the challenge: new therapies for tuberculosis.

Authors:  Emily B Wong; Keira A Cohen; William R Bishai
Journal:  Trends Microbiol       Date:  2013-06-11       Impact factor: 17.079

Review 9.  Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis.

Authors:  Scott G Franzblau; Mary Ann DeGroote; Sang Hyun Cho; Koen Andries; Eric Nuermberger; Ian M Orme; Khisimuzi Mdluli; Iñigo Angulo-Barturen; Thomas Dick; Veronique Dartois; Anne J Lenaerts
Journal:  Tuberculosis (Edinb)       Date:  2012-08-30       Impact factor: 3.131

10.  PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release.

Authors:  Ramandeep Singh; Ujjini Manjunatha; Helena I M Boshoff; Young Hwan Ha; Pornwaratt Niyomrattanakit; Richard Ledwidge; Cynthia S Dowd; Ill Young Lee; Pilho Kim; Liang Zhang; Sunhee Kang; Thomas H Keller; Jan Jiricek; Clifton E Barry
Journal:  Science       Date:  2008-11-28       Impact factor: 63.714
View more
  2 in total

1.  Syntheses and Biological Evaluations of Highly Functionalized Hydroxamate Containing and N-Methylthio Monobactams as Anti-Tuberculosis and β-Lactamase Inhibitory Agents.

Authors:  Mark W Majewski; Kyle D Watson; Sanghyun Cho; Patricia A Miller; Scott G Franzblau; Marvin J Miller
Journal:  Medchemcomm       Date:  2015-10-05       Impact factor: 3.597

2.  Synthesis and Characterization of N-Methyl Fatty Hydroxamic Acids from Ketapang Seed Oil Catalyzed by Lipase.

Authors:  Dedy Suhendra; Erin Ryantin Gunawan; Hajidi Hajidi
Journal:  Molecules       Date:  2019-10-29       Impact factor: 4.411
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.